03
November 2021
First Patient Dosed in Clinical Study of KN046 in Combination with ALK-1 Antibody in Advanced or Refractory Solid Tumors
to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of KN046 in combination with ALK-1 antibody in patients with advanced or refractory solid tumors, including hepatoce...